Shares of Pacific Biosciences of California (NASDAQ:PACB) closed deep in red week following the news that the healthcare firm terminated its deal with Roche Holding Ltd. (ADR)(OTCMKTS:RHHBY). The two companies deal was signed in 2013. It permitted Roche to advance diagnostic products using Pacific SMRT technology and sell them across globe. Meanwhile, the company maintained its right to commercialize its products for fields outside the scope of human in vitro diagnostics.

The highlights

The deal allowed Roche the privilege to terminate the agreement for any reason. News came last week that Roche’s management decided to use that option. Dr. Michael Hunkapiller, the CEO of Pacific Biosciences, said that the clinical market and research industry and regulatory environment have grown in the last three years since they made a deal with Roche.

While they are upset with Roche’s decision to cancel the agreement, they know the in-and-out of this market and this decision does not have any impact on their near-term plans for business expansion in the same industry.

Roche’s decision to terminate the deal with Pacific poses huge questions on the firm’s future. It should be noted that Roche is a massive firm with resources that far surpass that of Pacific Biosciences. Many shareholders believed that this association would yield results for many years to come. However, Roche’s decision to cancel the deal puts an end to market hopes.

Looking at the bright side, it is worth mentioning that Pacific Biosciences is optimistic on its near-term future. Management reaffirmed that its service and product revenue can record growth of over 55% in 2016. Also, the company expects its revenue to surge by 40% to 60% in 2017. It’s all encouraging, but since this update poses new concerns about the firm’s long-term future, it is better to adopt a cautionary approach towards investing in the stock.

In the last trading session, the stock price of Pacific Biosciences gained marginally to close at $3.54.

Previous articleCommunity Health Systems (NYSE:CYH) Reports Definitive Deal to Sell Two Washington Hospitals
Next articleTerraForm Global Inc (NASDAQ:GLBL) Continues With Its Decline
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.